Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells… Read more
Lyell Immunopharma Inc (LYEL) - Total Liabilities
Latest total liabilities as of September 2025: $78.84 Million USD
Based on the latest financial reports, Lyell Immunopharma Inc (LYEL) has total liabilities worth $78.84 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lyell Immunopharma Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Lyell Immunopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lyell Immunopharma Inc Competitors by Total Liabilities
The table below lists competitors of Lyell Immunopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
Thailand | ฿130.75 Billion |
|
Guangdong Hongteo Accurate Technology Co Ltd
SHE:300176
|
China | CN¥1.37 Billion |
|
Shandong Luyang Share Co Ltd
SHE:002088
|
China | CN¥632.73 Million |
|
Ronshin Group A
SHE:301231
|
China | CN¥74.33 Million |
|
Kyung Dong Navien Co Ltd
KO:009450
|
Korea | ₩718.81 Billion |
|
Piovan S.p.A
F:PV0
|
Germany | €321.49 Million |
|
Selamat Sempurna Tbk
JK:SMSM
|
Indonesia | Rp891.25 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Lyell Immunopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lyell Immunopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lyell Immunopharma Inc (2019–2024)
The table below shows the annual total liabilities of Lyell Immunopharma Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $108.03 Million | +13.63% |
| 2023-12-31 | $95.08 Million | -8.85% |
| 2022-12-31 | $104.31 Million | -47.22% |
| 2021-12-31 | $197.62 Million | +4.10% |
| 2020-12-31 | $189.84 Million | +28.64% |
| 2019-12-31 | $147.58 Million | -- |